Key result
In vivo animal models have contributed to cardiac drug development, but there remains a clear need to lessen the gap between human and experimental models to improve clinical relevance.
This review highlights the utility and limitations of various in vivo animal models in the development and screening of cardiac drugs.
Answers are grounded in this paper and cite their sources.
Supports cautious translation of animal cardiac drug data to patients; leaves open development of more human-relevant models.
Cardiac disease is the top cause of human mortality in the Western world. Current drug therapy for cardiac disease has been established via experimental studies using a variety of in vivo animal models. The purpose of this review is to discuss the features (advantages and limitations) of the mainly used in vivo models of cardiac disease and provide the reader with an overview of how they can be utilized in the development and screening of cardiac drugs. A search for articles focusing on and including in vivo models for the main areas of cardiac diseases was performed on PubMed. We also searched the reference lists of identified articles for further original articles. Large and small animal models including genetically modified ones have made accomplishments in the process of cardiac drug development with different clinical relevance. However, there is still a clear need for lessening the gap between human and experimental models by improving in vivo models.
No takes yet. Share an insight, caveat, or question.
Rokutan et al. (2009) conducted a review in Cardiac disease. In vivo animal models was evaluated. In vivo animal models have contributed to cardiac drug development, but there remains a clear need to lessen the gap between human and experimental models to improve clinical relevance.
Synapse has enriched 10 related papers. Consider them for comparative context: